#1COPYRIGHT © ABCELLERA Q2 2022 BUSINESS UPDATE AUGUST 9, 2022 AbCellera#2Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 2 DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could,” “would,” “should," “expect," "“intend," "plan," "anticipate," "believe," "estimate," "predict," "project,” “potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.#3Q2 2022. BUSINESS UPDATE SUMMARY. MAINTAINING A STRONG CASH POSITION & EXPANDING COMPETITIVE ADVANTAGE Current environment presents challenges for would-be competitors, extending our competitive advantage. $1B+ in cash, cash equivalents & marketable securities Our business model provides value to companies prioritizing innovation, efficiency and capital preservation. 164 cumulative programs under contract Rationalization across the industry will likely lead to a consolidation of talent. 88 cumulative programs started#4Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 4 TECHNOLOGY AS A LEVER TARGET TO IND IS ONE OF THE MOST COMPLEX & TECHNOLOGY-INTENSIVE PATHS IN ANY SECTOR Target Identification IDEATION Drug Discovery regulations, technology, science, manufacturing, lab space, talent PRODUCT CREATION 3 to 5 years 1000+ steps Clinical Development PRODUCT TESTING 7 to 10 years#5Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 5 VALUE CREATION SIGNIFICANT OPPORTUNITIES TO UNLOCK VALUE We aim to deliver value in three ways: by making drug development faster • by doing things that haven't been done before by leveling the playing field for partners, to empower a broad ecosystem of innovators $200M+ by accelerating approval of an average antibody drug by 1 year NPV Billions by being first to market sales, profit, value $100B+ unlocked by drugging the undruggable new market opportunities Millions from not having to reinvent the wheel small biotech savings#6Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 6 PARTNERSHIPS PARTNERING WITH PREMIER VENTURE CAPITAL FIRMS TO UNLOCK EARLY-STAGE INNOVATORS 6 PORTFOLIO COMPANY OF ATLAS VENTURE 3 targets multi-year NEW PROGRAMS UNDER CONTRACT a multiple indications undisclosed 3 targets multi-year Qmultiple indications 8 POTENTIAL PROGRAMS PORTFOLIO COMPANIES OF VERSANT ventures#7Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 7 TECHNOLOGY DEVELOPMENT. T-CELL ENGAGER PLATFORM ADVANCING NEW T-CELL ENGAGER CANCER THERAPIES Our data indicate that our CD3 panel of 200+ unique antibodies bind to a wide variety sites on the CD3 complex and is capable of constructing bispecific antibodies with a very wide range of functional activities - exactly what is needed to build tunable, optimized therapeutic T-cell engagers. CD3 + EGFR BISPECIFIC ANTIBODIES PROOF OF CONCEPT Bispecifics induced a wide range of T cell activation. Bispecifics were identified that effectively kill tumor cells with either no or very low cytokine release, suggesting these molecules could overcome key hurdles to getting into the clinic.#8Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 8 TECHNOLOGY DEVELOPMENT. PRE-PARTNERED PROGRAMS TECH DEVELOPMENT MAY GENERATE ASSETS FOR PARTNERING Pandemic Response Platform Technology-intensive challenge requiring complex integration to deliver antibody therapies quickly and bring new treatments to address emerging variants. T-Cell Engager Platform Untapped market opportunity in an area with a high technical barrier to entry and a rich target space that includes many targets. GPCRs & lon Channels Platform High-value, well-validated targets that have been intractable using fragmented approaches and traditional technology.#9Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 9 TECHNOLOGY DEVELOPMENT. VALUE OF PRE-PARTNERED PROGRAMS 2 YEARS OF TECH DEVELOPMENT 2 COVID ANTIBODY TREATMENTS 2.5M+ PATIENTS TREATED We had spent 2 years developing our technology specifically for pandemic response prior to the emergence of COVID-19 and initiated our work before entering into a partnership with Eli Lilly. Bamlanivimab was the first antibody to be authorized by FDA, and bebtelovimab continues to be used to combat the virus, remains effective against all known variants of concern, and is still the most potent COVID-19 antibody treatment available.#10o COPYRIGHT © ABCELLERA Q2 2022 FINANCIALS UPDATE#11FINANCIALS Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 11 Strong portfolio growth. Total # of Programs Under Contract Total # of Discovery Partners 38 164 Cumulative # of Program Starts 90 80 70 60 50 40 30 20 10 O 88 2014 2015 2016 2017 2018 2019 2020 2021 2022 Q2 WITHOUT downstream participation + WITH downstream participation 6 5 4 3 2 1 O Cumulative # of Molecules in the Clinic 6 2014 2015 2016 2017 2018 2019 2020 2021 2022 Q2 Note: Showing year-end figures except for most recent quarter. Historical results are not necessarily indicative of future results.#12FINANCIALS Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 12 6 molecules in the clinic. MOLECULE bamlanivimab (LY-CoV555) bebtelovimab (LY-CoV1404) NBL-012 NBL-015 undisclosed IVX-01 STAGE Marketed, Emergency Use Authorization (EUA) Marketed, Emergency Use Authorization (EUA) Phase 1 completed IND/CTA authorized IND/CTA authorized Clinical field study PARTNER Lilly Lilly NovaRock BOTHERAPEUTICS NovaRock BOTHERAPEUTICS undisclosed Invetx™ THERAPEUTIC AREA ● • ● ● ● ● ● ● infectious disease - COVID-19 infectious disease - COVID-19 dermatology gastrointestinal disease immunology oncology undisclosed animal health PROGRAM TYPE AbCellera Discovery Partnership Trianni License AbCellera Discovery Partnership As of June 30, 2022#13FINANCIALS Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 13 $45.9M total revenue, driven by royalties for bebtelovimab. Revenue USD ROYALTIES MILESTONES LICENSING RESEARCH FEES $0.3M $27.6M $21.2M $1.0M $5.2M Q2 2021 $45.9M $33.2M $12.5M Q2 2022 $0.1M#14FINANCIALS Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 14 Operating expenses reflect strengthening of the platform. Operating Expenses USD RESEARCH & DEVELOPMENT $15.0M Q2 2021 +$11.6M $26.7M Q2 2022 SALES & MARKETING $1.3M Q2 2021 +$1.8M $3.1M Q2 2022 GENERAL & ADMIN $11.2M Q2 2021 +$3.2M $14.4M Q2 2022#15FINANCIALS Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 15 Net loss of $6.8M: equivalent to $0.02 (basic and diluted) per share. Earnings USD NET EARNINGS -$2.3M Q2 2021 -$6.8M Q2 2022 EARNINGS PER SHARE: BASIC AND DILUTED -$0.01 Q2 2021 -$0.02 Q2 2022#16FINANCIALS Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 16 Over $1 billion in total cash, equivalents, and marketable securities. Cash Flows USD $748M $247M $476M $25M 31-Dec-21 $373M OPERATING ($54M) INVESTING ($2M) FINANCING ($1M) FX $1,049M $232M Marketable Securities $792M Cash & Equivalents $25M Restricted Cash 30-Jun-22#1717 COPYRIGHT © ABCELLERA 15 Q2 2022 BUSINESS UPDATE YOU THANK